Kaneka Corporation

Kanegafuchi Kagaku Kogyo Kabushiki Kaisha

Kanegafuchi Chemical Industry Co., Ltd.

Activbiotics Pharma, LLC

Kazunori Hosoe

Takayoshi Hidaka

Kenji Fujii

Kiyoshi Watanabe

Katsuji Yamashita

Ikuo Katsumi

Taizo Kawabe

Yutaka Ariki

Tadayoshi Shiraishi

Keiji Kameyama

Takehiko Yamane

Naohiro Imai

Takeshi Domoto

Yoshio Shimada

Masaji Kawatsu

Hideo Kondo

Takahiro Ueda

Shiro Kitamura

Takuji Hashizume

Yasuyoshi Ueda

Hideyuki Kishida

Toshiaki Yamashita

Fumiyuki Kuze

Yasuhiro Saka

Jeffrey L Watts

Mitsuaki Kitano

Hiroshi Kubo

Hirokazu Sakamoto

Tadao Ono

Shinichi Sakashita

Robert J Yancey, Jr

Fumihiko Kanoo

Masanori Kato

George Todaro

Ribhi M Shawar

Fumihiko Kano

Yoshiyuki Shinagawa

Taizou Kawabe

Toshihide Fujii

To maintain physical fitness and health of middle-aged and older persons living in the threshold of the aging society, the present invention provides a fatigue reducing agent which is highly effective for preventing and reducing fatigue, wherein the agent is made of a composition of substances that are very safe so that long-term administration is possible. A composition containing reduced coenzyme Q was found to be effective for preventing and reducing fatigue, including muscle fatigue. Since the fatigue reducing effect of the composition of the present invention is seen not only in young rats but also more pronounced in aged rats, the present invention can provide the fatigue reducing agent which is very useful, especially, for middle-aged and older persons as well as for young people.

Fatigue reducing agent

The present invention relates to a method for stabilizing reduced coenzyme Q, which is useful as an ingredient in good foods, functional nutritive foods, specific health foods, nutritional supplements, nutrients, animal drugs, drinks, feeds, cosmetics, medicines, remedies, preventive drugs, etc., and to a composition therefor. The composition comprises reduced coenzyme Q, a fat and oil (excluding olive oil) and/or a polyol, and doesn't substantially inhibit the stabilization of reduced coenzyme Q. Additionally, the composition is a reduced coenzyme Q-containing composition which comprises reduced coenzyme Q, a polyglycerol fatty acid ester, and a fat and oil and/or a polyol.

[object Object]

The present invention provides a method for stabilizing reduced coenzyme Q, which is useful as a food, nutritional product, nutritional supplement, animal drug, drink, feed, cosmetic, pharmaceutical product, therapeutic drug, prophylactic drug and the like. The present invention also provides a method of producing a reduced coenzyme Q-containing composition which includes the co-presence of reduced coenzyme Qand reduced coenzyme Qand/or reduced coenzyme Q.

The present invention relates to the supply of coenzyme Q which is highly useful in maintaining human health, and provides a method and preparations whereby coenzyme Q can be efficiently supplied to patients having difficulties in oral administration, aged having swallowing difficulties and patients with diseases caused by topical disorders. It is found that the coenzyme Q concentration in the blood or topical mucosae can be elevated by using a composition for transmucosal administration containing oxidized coenzyme Q and/or reduced coenzyme Q as the active ingredient, wherein the total content of the oxidized coenzyme Q and the reduced coenzyme Q amounts to 0.0001 to 99% by weight of the whole composition.

Composition for transmucosal administration containing conenzyme Q as the active ingredient

The present invention provides a reduced coenzyme Q-containing solution capable of being retained more stably against oxidation, by using a reduced coenzyme Q which is hydrophobic and susceptible to oxidation and thus unstable. The aqueous solution containing a reduced coenzyme Q obtained in the present invention is a solution containing a reduced coenzyme Q and an antioxidant such as vitamin C and/or a chelating agent such as ethylenediaminetetraacetic acid.

Stabilized compositions of aqueous reduced coenzyme Q solution

The present invention provides an antioxidative composition with high safety, which is capable of lessening oxidative stress due to active oxygen species, free radicals, or the like in vivo, thereby preventing the occurrence or worsening of a disease. It was confirmed that by using a composition containing oxidized coenzyme Q and/or reduced coenzyme Q, the amount of urinary 8-hydroxydeoxyquanosine can be decreased in normal or diabetic animals. Also, in histopathological research of the spleens of diabetic rats, it was confirmed that spleen tissue denaturation caused by oxidative stress can be prevented. It was thus found that oxidative stress in vivo can be lessened. According to the present invention, oxidative stress in vivo can be lessened by using a composition containing coenzyme Q as an active ingredient.

Compositions for lessening oxidative stress

The present invention has for its object to provide a method and a composition for achieving a more efficient recovery of the antioxidant activity of plasma LDL, or even augmentation thereof, which has been depressed by the use of an antihyperlipidemic or cholesterol-lowering drug to thereby insure a potentiated antiarteriosclerotic efficacy. A method for inhibiting arteriosclerosis, which comprises using a combination of a cholesterol-lowering agent and a reduced coenzyme Qrepresented by the following formula (1), and a composition for inhibiting arteriosclerosis containing both a cholesterol-lowering agent and said reduced coenzyme Q.

Method and composition for inhibiting arteriosclerosis

Use of rifamycin derivative for treating mastitis in a domestic animal

Antibacterial compositions comprising (1) a rifamycin derivative represented by the formula (I) or its physiologically acceptable salt, and (2) a proton pump inhibitor (a) or a bismuth preparation (b) wherein the components (1) and (2) are used in such amounts as producing a synergistic effect against drugs and remedies for digestive organ diseases which contain the antibacterial compositions, process for producing them, and pharmaceutical preparations related to the antibacterial compositions. The compositions can be administered to patients with digestive diseases caused by infection of in a smaller dose and at a lower administration frequency as compared with conventional remedies.

Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith

A method for treating a digestive organ disease caused by the infection of Helicobacter, comprising administering a rifamycin derivative expressed by the formula (I), or a physiologically acceptable salt thereof ##STR1##

Treatment of disease caused by infection of Helicobacter

A method for treatment of diseases caused by Chlamydia infection is disclosed comprising administering a rifamycin of the formula (I): ##STR1## wherein R.sup.1 is hydrogen atom or acetyl, and X is oxygen, sulfur or a group NR, in which R is hydrogen, an alkyl group having 1 to 7 carbon atoms or a group of the formula (II): ##STR2## in which n is an integer of 1 to 3; or a physiologically acceptable salt thereof.

Method for treating chlamydia infectious diseases by rifamycin derivative

A hydroxystyrene derivative represented by the formula (I): ##STR1## wherein when R.sup.1 and R.sup.2 : phenyl group, benzyl group or phenethyl group, or R.sup.1 : R.sup.5 O- (R.sup.5 : H, a C.sub.1 to C.sub.5 alkyl group or benzyl group) and R.sup.2 : benzyl group or PhSCH.sub.2, R.sup.3 and R.sup.4 are taken together to represent --CONH--CS--S--, ##STR2## (X.sup.1 : H, a halogen, methyl group, ethyl group, R.sup.7 O-- (R.sup.7 : methyl or ethyl group), nitro group, aminosulfonyl group or amino group, m.sup.1 : 1 or 2), pyridyl group, furyl group or thienyl group, n.sup.1 : an integer of 0 to 3); when R.sup.1 and R.sup.2 : phenyl group, benzyl group or phenethyl group, or R.sup.1 : R.sup.5 O-- (R.sup.5 : as defined above) and R.sup.2 : benzyl group, R.sup.3 : cyano group and R.sup.4 : a carbamoyl group, or R.sup.3 and R.sup.4 are taken together to represent --CO--Y--CH.sub.2 CH.sub.2 -- (Y: O or --NH--) or ##STR3## and when R.sup.1 and R.sup.2 : a C.sub.1 to C.sub.3 alkyl group, R.sup.3 and R.sup.4 are taken together to represent ##STR4## (n.sup.1, R.sup.6 : as defined above), or a salt thereof. The hydroxystyrene derivative or a salt thereof is a compound which is useful as an active ingredient of an antiallergic agent, a 5-lipoxygenase inhibiting agent, an antibacterial agent, a tyrosine kinase inhibiting agent, an ultraviolet absorber or a reverse transcriptase inhibiting agent, and also is useful as an intermediate for preparing various organic compounds.

Hydroxystyrene compounds having tyrosine kinase inhibiting activity

A hydroxystyrene derivative represented by the formula (I): ##STR1## wherein when R.sup.1 and R.sup.2 : phenyl group, benzyl group or phenethyl group, or R.sup.1 : R.sup.5 O-- (R.sup.5 : H, a C.sub.1 to C.sub.5 alkyl group or benzyl group) and R.sup.2 : benzyl group or PhSCH.sub.2, R.sup.3 and R.sup.4 are taken together to represent --CONH--CS--S--, ##STR2## (X.sup.1 : H, a halogen, methyl group, ethyl group, R.sup.7 O-- (R.sup.7 : methyl or ethyl group), nitro group, aminosulfonyl group or amino group, m.sup.1 : 1 or 2), pyridyl group, furyl group or thienyl group, n.sup.1 : an integer of 0 to 3); when R.sup.1 and R.sup.2 : phenyl group, benzyl group or phenethyl group, or R.sup.1 : R.sup.5 O-- (R.sup.5 : as defined above) and R.sup.2 : benzyl group, R.sup.3 : cyano group and R.sup.4 : a carbamoyl group, or R.sup.3 and R.sup.4 are taken together to represent --CO--Y--CH.sub.2 CH.sub.2 -- (Y: O or --NH--) or ##STR3## and when R.sup.1 and R.sup.2 : a C.sub.1 to C.sub.3 alkyl group, R.sup.3 and R.sup.4 are taken together to represent ##STR4## (n.sup.1, R.sup.6 : as defined above), or a salt thereof. The hydroxystyrene derivative or a salt thereof is a compound which is useful as an active ingredient of an antiallergic agent, a 5-lipoxygenase inhibiting agent, an antibacterial agent, a tyrosine kinase inhibiting agent, an ultraviolet absorber or a reverse transcriptase inhibiting agent, and also is useful as an intermediate for preparing various organic compounds.

1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have

A rifamycin derivative having the formula (I): ##STR1## wherein A is a group having the formula: ##STR2## in which R.sup.1 is an alkyl group having 4 or 5 carbon atoms or an alkenyl group having 3 to 5 carbon atoms, or a group having the formula: in which n is 3 or 4; or a pharmaceutically acceptable salt thereof. The rifamycin derivative (I) exhibits a strong antibacterial activity against Gram-positive bacteria and acid-fast bacteria, and also exhibits a strong antibacterial activity against tubercle bacilli.

3'-hydroxybenzoxazinorifamycin derivative, process for preparing the

Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors

Growing community of inventors

Takasago, Japan

Kazunori Hosoe